SPC530
Samsetning af (a) vanzacaftor eða lyfjafræðilega viðunandi salti þar af, ákjósanlega kalsíumsalti þar af, (b) tezacaftor eða lyfjafræðilega viðunandi salti þar af, og (c) deutivacaftor eða lyfjafræðilega viðunandi salti þar af / A combination of (a) vanzacaftor or a pharmaceutically acceptable salt thereof, preferably a calcium salt thereof, (b) tezacaftor or a pharmaceutically acceptable salt thereof, and (c) deutivacaftor or a pharmaceutically acceptable salt thereof
Status:
UmsóknApplication date:
2.12.2025Application published:
14.1.2026
Medicine name:
AlyftrekMedicine for children:
No
Timeline
Today
2.12.2025Application
14.1.2026Publication
Marketing license
Foreign authorization number:
EU/1/25/1943Date:
30.6.2025
Owner
Name:
Vertex Pharmaceuticals IncorporatedAddress:
50 Northern Avenue, Boston, MA 02210 US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113 Reykjavík
Patent
Number:
EP3880197